Patents Assigned to Celgene Corporation
  • ANTI-BCMA ANTIBODY CONJUGATE, COMPOSITIONS COMPRISING THE SAME, AND METHODS OF MAKING AND USING THE SAME
    Publication number: 20220323599
    Abstract: The present disclosure relates to antibody conjugates with binding specificity for BCMA (BCMA) and its isoforms and homologs, and compositions comprising the antibody conjugates, including pharmaceutical compositions. Also provided are methods of producing the antibody conjugates and compositions as well as methods of using the antibody conjugates and compositions, such as in therapeutic and diagnostic methods.
    Type: Application
    Filed: May 1, 2020
    Publication date: October 13, 2022
    Applicant: CELGENE CORPORATION
    Inventors: John LEE, Ryan STAFFORD, Alice YAM, Xiaofan LI, Abigail YU, Amandeep GAKHAL
  • Methods for treating cancer and the use of biomarkers as a predictor of clinical sensitivity to therapies
    Patent number: 11460471
    Abstract: A method of identifying a subject having cancer who is likely to be responsive to a treatment compound, comprising administering the treatment compound to the subject having the cancer; obtaining a sample from the subject; determining the level of a biomarker in the sample from the subject; and diagnosing the subject as being likely to be responsive to the treatment compound if the level of the biomarker in the sample of the subject changes as compared to a reference level of the biomarker; wherein the treatment compound is a compound of Formula I:
    Type: Grant
    Filed: April 3, 2020
    Date of Patent: October 4, 2022
    Assignee: CELGENE CORPORATION
    Inventors: Ellen Filvaroff, Antonia Lopez-Girona, Gang Lu
  • Antiproliferative compounds and bispecific antibody against BCMA and CD3 for combined use
    Patent number: 11439637
    Abstract: Provided herein is are methods of using 4-(4-(4-(((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)oxy)methyl)benzyl)piperazin-1-yl)-3-fluorobenzonitrile, or an enantiomer, a mixture of enantiomers, a tautomer, or a pharmaceutically acceptable salt thereof and a bispecific antibody specifically binding to human B cell maturation antigen (BCMA) and to human CD3? (CD3) provided herein, in treating, preventing or managing multiple myeloma.
    Type: Grant
    Filed: May 22, 2019
    Date of Patent: September 13, 2022
    Assignee: Celgene Corporation
    Inventors: Daniel W. Pierce, Lilly L. Wong
  • METHODS OF TREATING CANCER BY TARGETING COLD TUMORS
    Publication number: 20220273654
    Abstract: Methods are provided for the treatment of cancer or neoplastic diseases and the like, by administering 4-[2-(4-amino-piperidin-1-yl)-5-(3-fluoro-4-methoxy-phenyl)-1-methyl-6-oxo-1,6-dihydro-pyrimidin-4-yl]-2-fluoro- benzonitrile (compound of Formula (I)) or a pharmaceutically acceptable salt thereof, and pharmaceutical compositions comprising compounds useful for the inhibition of lysine specific demethylase-1 (LSD-1) to patients in need thereof. Methods are further drawn to administering compositions described herein to patients having neoplastic cells that express RCOR2.
    Type: Application
    Filed: June 12, 2020
    Publication date: September 1, 2022
    Applicant: Celgene Corporation
    Inventors: Ellen Filvaroff, Brian Fox, Ida Aronchik, Tracy Chow
  • Antibodies with low immunogenicity and uses thereof
    Patent number: 11427632
    Abstract: Provided herein are antibodies and antigen-binding fragments thereof with low or no immunogenicity in humans and optionally with desirable manufacturing properties. Also provided are compositions comprising such antibodies or antigen-binding fragments, methods of using such antibodies, and methods for making such antibodies.
    Type: Grant
    Filed: July 5, 2017
    Date of Patent: August 30, 2022
    Assignee: CELGENE CORPORATION
    Inventors: Jeffrey C. Johnson, Lawrence Dearth, Haralambos Hadjivassiliou, Jeonghoon Sun, Kandasamy Hariharan
  • Compositions and methods for inducing conformational changes in cereblon and other E3 ubiquitin ligases
    Patent number: 11419861
    Abstract: Provided herein are compositions, therapeutic methods, screening methods, computational methods and biomarkers based upon the elucidation of the interaction among cereblon, its substrates and certain compounds or agents, including small molecules, peptides, and proteins.
    Type: Grant
    Filed: April 17, 2020
    Date of Patent: August 23, 2022
    Assignee: CELGENE CORPORATION
    Inventors: Philip Chamberlain, Brian E. Cathers, Antonia Lopez-Girona
  • Arylmethoxy isoindoline derivatives and compositions comprising and methods of using the same
    Patent number: 11414399
    Abstract: Provided are 4?-arylmethoxy isoindoline compounds, and pharmaceutically acceptable salts, solvates, clathrates, stereoisomers, and prodrugs thereof. Methods of use, and pharmaceutical compositions of these compounds are disclosed.
    Type: Grant
    Filed: March 31, 2020
    Date of Patent: August 16, 2022
    Assignee: CELGENE CORPORATION
    Inventors: Hon-Wah Man, Roger Shen-Chu Chen, George W. Muller, Alexander L. Ruchelman, Ehab M. Khalil, Weihong Zhang
  • AZACITIDINE IN COMBINATION WITH VENETOCLAX, GILTERITINIB, MIDOSTAURIN OR OTHER COMPOUNDS FOR TREATING LEUKEMIA OR MYELODYSPLASTIC SYNDROME
    Publication number: 20220249528
    Abstract: Provided herein are methods for using 5-azacytidine in combination with one or more additional agents to treat diseases and disorders including acute myeloid or myelogenous leukemia (AML). Other disease and disorders those associated with abnormal cell proliferation, myelodysplastic syndromes (MDS), abnormal cell proliferation, hematologic disorders, and immune disorders, among others.
    Type: Application
    Filed: June 19, 2020
    Publication date: August 11, 2022
    Applicant: CELGENE CORPORATION
    Inventors: CL Beach, Diana R. Dunshee, Daniel E. Lopes de Menezes, Kyle MacBeth, Yumin Dai, Shelonitda Rose, Jessica Jang, Mark Frattini
  • Solid forms comprising 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione and a coformer, compositions and methods of use thereof
    Patent number: 11406629
    Abstract: Provided herein are solid forms comprising (a) 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione and (b) a coformer. Pharmaceutical compositions comprising the solid forms (e.g., cocrystals) and methods for treating, preventing and managing various disorders are also disclosed.
    Type: Grant
    Filed: October 1, 2020
    Date of Patent: August 9, 2022
    Assignee: Celgene Corporation
    Inventors: G. Patrick Stahly, David Jonaitis, Ho-Wah Hui, Kevin J. Klopfer
  • BCMA-binding antibodies and uses thereof
    Patent number: 11401336
    Abstract: Antibody species that bind B-Cell Maturation Antigen (BCMA) are provided as well as methods of depleting BCMA-expressing cells in a patient in need thereof, comprising administering a therapeutically effective amount of the antibody species or an entity comprising a BCMA binding fragment thereof. Methods of treating B cell-related disorders associated with BCMA expression in a patient in need thereof are provided, comprising administering to the patient a therapeutically effective amount of the antibody species or an entity comprising a BCMA binding fragment thereof.
    Type: Grant
    Filed: February 20, 2019
    Date of Patent: August 2, 2022
    Assignee: CELGENE CORPORATION
    Inventors: Mahan Abbasian, Henry Chan, Kandasamy Hariharan, Jeonghoon Sun, Andrew Wurmser
  • Solid forms of 2-(4-chlorophenyl)-N-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)-2,2-difluoroacetamide, and their pharmaceutical compositions and uses
    Patent number: 11401257
    Abstract: Solid forms comprising 2-(4-chlorophenyl)-N-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)-2,2-difluoroacetamide, compositions comprising the solid forms, methods of making the solid forms and methods of their uses are disclosed.
    Type: Grant
    Filed: March 18, 2020
    Date of Patent: August 2, 2022
    Assignee: CELGENE CORPORATION
    Inventors: Paul F. Fernandez, Antonio C. Ferretti, Ying Li, Weihong Zhang
  • Methods for screening cereblon modifying compounds
    Patent number: 11402372
    Abstract: A method of screening a cereblon modifying compound for treating a disease or disorder, comprising: obtaining a sample; determining a first protein level of SALL4; administering the cereblon modifying compound to the sample; determining a second protein level of SALL4; comparing the first level and the second protein level of SALL4 to determine if the cereblon modifying compound induces degradation of SALL4; and selecting the cereblon modifying compound that does not induce degradation of SALL4.
    Type: Grant
    Filed: January 10, 2019
    Date of Patent: August 2, 2022
    Assignee: CELGENE CORPORATION
    Inventors: Mary Matyskiela, Philip Chamberlain, Suzana Sturlini Couto, Katherine Stamp, Philip J. Sherratt, Gang Lu, Julia Hui
  • Tablet compositions
    Patent number: 11389454
    Abstract: Provided herein is a tablet comprising 2-methyl-1-[(4-[6-(trifluoromethyl)pyridin-2-yl]-6-{[2-(trifluoromethyl)pyridin-4-yl]amino}-1,3,5-triazin-2-yl)amino]propan-2-ol or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: September 6, 2017
    Date of Patent: July 19, 2022
    Assignees: CELGENE CORPORATION, SERVIER PHARMACEUTICALS LLC
    Inventors: Sreenivas S. Bhat, Scott Burnside, Darshan Parikh, Chong-Hui Gu, Syed Altaf
  • Methods of treating non-Hodgkin lymphoma using 2-(2,6-dioxopiperidin-3-yl)-4-((2-fluoro-4-((3-morpholinoazetidin-1-yl)methyl)benzyl)amino)isoindoline-1,3-dione
    Patent number: 11390617
    Abstract: Provided herein are methods of using 2-(2,6-dioxopiperidin-3-yl)-4-((2-fluoro-4-((3-morpholinoazetidin-1-yl)methyl)benzyl)amino)isoindoline-1,3-dione, or an enantiomer, a mixture of enantiomers, a tautomer, an isotopolog, or a pharmaceutically acceptable salt thereof, alone or in combination with rituximab, for treating, preventing or managing non-Hodgkin lymphoma.
    Type: Grant
    Filed: April 9, 2020
    Date of Patent: July 19, 2022
    Assignee: CELGENE CORPORATION
    Inventors: Maria Soraya Carrancio Anton, Tonia J. Buchholz, Antonia Lopez-Girona, Rama Krishna Narla, Michael Pourdehnad
  • Solid forms comprising (s)-4-(4-(4-(((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)oxy)methyl)benzyl)piperazin-1-yl)-3-fluorobenzonitrile and salts thereof, and compositions comprising and methods of using the same
    Patent number: 11370777
    Abstract: Provided herein are formulations, processes, solid forms and methods of use relating to salts of and solid forms comprising free base or salts of (S)-4-(4-(4-(((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)oxy)methyl)benzyl)piperazin-1-yl)-3-fluorobenzonitrile.
    Type: Grant
    Filed: January 8, 2020
    Date of Patent: June 28, 2022
    Assignee: Celgene Corporation
    Inventors: Gerald D. Artman, III, Antonio C. Ferretti, Lianfeng Huang, Udaykumar Jain, Hon-Wah Man, Paula A. Tavares-Greco, Wenju Wu, Nancy Nienhua Tsou, Zhiwei Yin
  • Antiproliferative compounds, and their pharmaceutical compositions and uses
    Patent number: 11365184
    Abstract: Compounds of formula A-I and B-I, compositions comprising the compounds, methods of making the compounds and methods of their uses are disclosed.
    Type: Grant
    Filed: March 6, 2020
    Date of Patent: June 21, 2022
    Assignee: Celgene Corporation
    Inventors: Matthew D. Alexander, Matthew D. Correa, Joshua Hansen, Raj Kumar Raheja, John Sapienza
  • Substituted 4-aminoisoindoline-1,3-dione compounds, compositions thereof, and methods of treatment therewith
    Patent number: 11358952
    Abstract: Provided herein are 4-aminoisoindoline-1,3-dione compounds having the following structure: wherein R, Ring A, and n are as defined herein, compositions comprising an effective amount of a 4-aminoisoindoline-1,3-dione compound, and methods for treating or preventing disorders.
    Type: Grant
    Filed: April 22, 2019
    Date of Patent: June 14, 2022
    Assignee: Celgene Corporation
    Inventors: Matthew D. Alexander, Soraya Carranclo, Matthew D. Correa, Virginia Heather Sharron Grant, Joshua Hansen, Roy L. Harris, Dehua Huang, Timothy S. Kercher, Antonia Lopez-Girona, Mark A. Nagy, Veronique Plantevin-Krenitsky
  • Combination therapies comprising apremilast and Tyk2 inhibitors
    Patent number: 11357775
    Abstract: Provided herein are methods of treating diseases and disorder responsive to the inhibition of PDE4 comprising administering apremilast and a Tyk2 inhibitor to a subject. Also provided herein are pharmaceutical compositions comprising apremilast and a Tyk2 inhibitor.
    Type: Grant
    Filed: April 30, 2019
    Date of Patent: June 14, 2022
    Assignee: Celgene Corporation
    Inventors: Peter Henry Schafer, Robert Plenge, Mary Adams, Lisa Beebe, Gilles Buchwalter, Tiffany Carr, Te-chen Tzeng
  • Animal and human anti-malarial agents
    Patent number: 11344554
    Abstract: Provided herein are Purine Compounds of Formula (I) or pharmaceutically acceptable salts, tautomers, isotopologues, or stereoisomers thereof, wherein R1, R2, and R3 are as defined herein, compositions comprising an effective amount of a Purine Compound, and methods for treating or preventing malaria comprising the administration of an effective amount of a Purine Compound.
    Type: Grant
    Filed: July 6, 2020
    Date of Patent: May 31, 2022
    Assignee: Celgene Corporation
    Inventors: Stacie S. Canan, Natalie Anne Hawryluk
  • METHODS FOR TREATING SYSTEMIC LUPUS ERYTHEMATOSUS AND THE USE OF BIOMARKERS AS A PREDICTOR OF CLINICAL SENSITIVITY TO THERAPIES
    Publication number: 20220160720
    Abstract: A method of determining a dose of a treatment compound for treating a subject having systemic lupus erythematosus (SLE), comprising obtaining a sample from the subject and measuring the gene expression level of IKZF3 and/or the gene expression levels of IFI27, IFI44, IFI44L, and RSAD2 in the sample.
    Type: Application
    Filed: September 30, 2021
    Publication date: May 26, 2022
    Applicant: CELGENE CORPORATION
    Inventors: Peter H. SCHAFER, Shaojun TANG